| Home |
| Site Map |
| News Archives |
| Environmental Health News |
| Illness Research |
| Articles |
| Treatment Information |
| Useful Lab Tests |
| Find A Doctor |
| Chemical Avoidance |
| Allergen Reduction |
| Water Filtration |
| Treatments & Products |
| Books |
| Dr. Teitelbaum's Column |
| Gloria Gilbčre's Column |
| Sick Building Syndrome |
| Seasonal Affective Disorder |
| Lyme Disease |
| Lupus |
| Hypoglycemia |
| Electrical Sensitivity |
| Adrenal Fatigue |
| Hypothyroidism |
| Sleep Apnea |
| Restless Leg Syndrome |
| Celiac Disease |
| Water Filters |
| SAD Light Boxes |
| Hepa Air Purifiers |
| HEPA Vacuum Cleaners |
| Nutritional Supplements |
| Home Test Kits |
| Cleaning Products |
| Personal Care |
| LifeWave Patches |
|
|
| Research - Candida & Gut Dysbiosis Research | |
|
Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1357-61.
Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication.
Duman DG, Bor S, Ozutemiz O, Sahin T, Oguz D, Istan F, Vural T, Sandkci M, Isksal F, Simsek I, Soyturk M, Arslan S, Sivri B, Soykan I, Temizkan A, Bessk F, Kaymakoglu S, Kalayc C.
Department of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey.
BACKGROUND AND AIM: Antibiotic-associated diarrhoea may develop during or following Helicobacter pylori eradication. We aimed to evaluate the efficacy and safety of Saccharomyces boulardii in preventing antibiotic-associated diarrhoea in patients receiving antibiotics for H. pylori eradication. METHODS: In a multicentre prospective clinical trial, patients with peptic ulcer disease or non-ulcer dyspepsia were enrolled to receive clarithromycin, amoxicillin and omeprazole for H. pylori eradication for 14 days. These patients were then randomized to receive either S. boulardii 500 mg twice daily (treatment group) or no treatment (control group). The primary outcome measure was the development of diarrhoea during (treatment period) or within 4 weeks after treatment (follow-up period). RESULTS: Of the 389 patients that were enrolled, 376 completed the study. Within the treatment period, diarrhoea developed in 5.9% of patients in the treatment group and in 11.5% of patients in the control group (P = 0.049); and in the follow-up period, diarrhoea developed in 1.0% of patients in the treatment group and in 3.8% of patients in the control group (P = 0.09). Overall diarrhoea rates throughout the whole study period were 6.9% in the treatment group and 15.6% in the control group (P = 0.007). No significant difference was observed between the treatment and control groups in terms of adverse events. CONCLUSION: S. boulardii is an effective and safe treatment for prevention of antibiotic-associated diarrhoea when given concomitantly to patients receiving H. pylori eradication.
Publication Types:
PMID: 16292090 [PubMed - indexed for MEDLINE]
Comments (0)
![]() Write comment
Discuss this article on the forums. (0 posts) |
|
| < Prev | Next > |
|---|
| searching for a doctor marie olene 11-12-08 23:42 |
| Skin Lesions Granuloma annulare Humminbyrd 11-05-08 20:39 |
| headaches, vertigo karenk 11-01-08 16:07 |
| All Canadians with MCS... LadyItchalot 10-20-08 04:42 |
| Skincare for those with Chemical Sensit... yayaba08 10-14-08 19:28 |
Subscribe to our newsletter and receive regular updates of our latest content: